Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib Neoadjuvant in BRAF-positive Anaplastic Thyroid Cancer
NCT04739566Phase 2Withdrawn
- Sponsor
- Saint Petersburg State University
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in anaplastic thyroid cancer (ATC), sponsored by Saint Petersburg State University. Planned start Jan 2021; status: withdrawn.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT04739566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739566.